[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:follicular-lymphoma:bcl6-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Follicular Lymphoma","BCL6 Gene",3,[8,16,22],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05890352","Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment",[12],"Phase 2","RECRUITING","2026-08-26T02:19:14.560989Z","2026-05-05T02:43:28.725480Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT04792489","DALY II USA\u002F MB-CART2019.1 for DLBCL",[12],"2026-08-26T02:16:01.910993Z","2026-07-19T19:36:05.118465Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT03223610","Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed\u002FRefractory B-cell Lymphoma",[26],"Phase 1\u002FPhase 2","2026-08-26T02:17:15.156099Z","2026-05-05T02:43:29.367349Z"]